Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities
Mario Sarbia(Pathologie Hamburg-West), Helmut E. Gabbert(Heinrich Heine University Düsseldorf), Philipp Dutkowski(University of Zurich), U. Fink(Technical University of Munich), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Rainhart Willers(Heinrich Heine University Düsseldorf), S. Seeber, Hansjörg Heep
International Journal of Cancer
February 19, 1999
Cited by 0
Related Papers
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
|Journal of Clinical Oncology|2004|460
Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis
|Genes & Development|2009|351
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
|Journal of Clinical Oncology|2003|320